OR9A1P: A Potential Drug Target and Biomarker (G26495)

Target Name: OR9A1P

NCBI ID: G26495

OR9A1P

OR9A1P: A Potential Drug Target and Biomarker

OR9A1P, a protein encoded in the OLPH gene, is a potential drug target and biomarker associated with various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. OR9A1P has unique features that make it an attractive target for drug development due to its stability, expressed in all cell types, and its potential to modulate the expression of genes involved in cell growth, differentiation, and survival.

OR9A1P is a 21-kDa transmembrane protein that plays a critical role in the regulation of cell adhesion and migration. It is a member of the PIK3CA gene family, which encodes a family of kinase A (PAK) proteins that are involved in the PI3K/ Akt signaling pathway. The PIK3CA gene has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

OR9A1P functions as a negative regulator of the PIK3CA gene by binding to the catalytic domain of the PAK protein. This interaction between OR9A1P and PAK results in the inhibition of PAK-mediated signaling pathways, including cell proliferation, differentiation, and survival. OR9A1P has been shown to be expressed in various cell types, including human cancer cells, neuroblastoma cells, and skeletal muscle cells.

The potential drug targets associated with OR9A1P include cancer cells, neurodegenerative disorders, and autoimmune diseases. Cancer cells, particularly those associated with the PI3K/Akt signaling pathway, can be targeted by drugs that inhibit the activity of OR9A1P and its downstream targets. For example , inhibitors of the PI3K/Akt signaling pathway, such as those derived from natural products or synthetic compounds, have been shown to be effective in various cancer types, including breast, ovarian, and colorectal cancers.

Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurodegeneration. The PIK3CA gene has been implicated in the development and progression of these disorders, and the inhibition of OR9A1P has has been suggested as a potential therapeutic approach.

Autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the dysregulation of the immune system, leading to inflammation and tissue damage. The PIK3CA gene has also been implicated in the development and maintenance of autoimmune diseases. In addition, OR9A1P has been shown to be involved in the regulation of immune cell function and the production of antibodies, which may contribute to its potential as a therapeutic target in autoimmune diseases.

In conclusion, OR9A1P is a protein with unique features that make it an attractive target for drug development due to its stability, expressed in all cell types, and its potential to modulate the expression of genes involved in cell growth, differentiation, and survival. The inhibition of OR9A1P's activity has been shown to be effective in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Further research is needed to fully understand the potential of OR9A1P as a drug target and biomarker.

Protein Name: Olfactory Receptor Family 9 Subfamily A Member 1 Pseudogene

Functions: Odorant receptor

The "OR9A1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR9A1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets